Replies to post #765741 on NorthWest Biotherapeutics Inc (NWBO)

[Galzus Research]

I don’t know why anyone here is hostile to TTF. It has equally strong data of improving OS with its own controversial interpretations

But TTF is completely not in conflict with DC immunotherapy. There is no reason that a patient getting DCVax couldn’t get TTF as well.

So I agree, but DCVax is an iterative improvement on GBM care, and TTF is also. No reason they wouldn’t both be used.